8th T-Cell Engager Therapeutics Summit

8th T‑Cell Engager Therapeutics Summit — Your Flagship TCE Meeting

The T‑cell engager field is evolving at an unprecedented pace. With multiple clinical approvals now validating the durability and therapeutic relevance of this modality, and a new wave of next‑generation solid tumor and autoimmune programs rapidly progressing toward the clinic, TCEs have firmly established themselves as one of the most transformative forces shaping the future of immunotherapy.

Over the past year, the landscape has seen a sharp rise in investment, strategic alliances, and high‑value partnerships. Landmark collaborations, including BMS × JanuX Therapeutics, Candid Therapeutics × WuXi Biologics, and AbbVie × EvolveImmune, underscore the growing confidence in immune‑redirecting platforms and the sector’s commitment to accelerating innovation across oncology and autoimmune disease.

Now moving from Boston to San Diego for 2026, the 8th T‑Cell Engager Therapeutics Summit remains the industry’s most comprehensive end‑to‑end meeting dedicated exclusively to advancing, optimizing, and translating TCEs. This case‑study‑driven forum equips engineering, discovery, R&D, translational, and clinical development teams with the actionable insights needed to design safer, more potent, durable, and precisely targeted TCEs for solid tumors. The agenda also shines a spotlight on new applications expanding engager biology into autoimmune and inflammatory indications.

If accelerating your TCE pipeline is a priority, this is the meeting you cannot afford to miss.

What’s New in 2026?

Two Brand‑New Parallel Tracks
Tailor your learning across two dedicated streams: Discovery & Engineering and Preclinical to Clinical Translation, enabling deep dives aligned to your role and pipeline stage.

Fresh Clinical Insights in Combination & Precision Immunotherapy
Hear directly from Amgen and Regeneron as they reveal new clinical evidence on chemo‑immunotherapy integration, co‑stimulation pairings, and combination‑ready TCE design for deeper, more durable responses in solid tumors.

Explore the Full Event Guide

120+ Industry Attendees
28+ Expert Speakers
8+ Hours of Networking
6 Deep‑Dive Workshops
1 Modality at the Center
The Only Forum Advancing TCEs Across Oncology & Autoimmune Disease

View the Full Program – See all sessions, speakers, and workshops: https://ter.li/fulua0